OS Therapies Inc. (OSTX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for OS Therapies Inc. for the period ended March 31, 2026. OS Therapies is a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma, primarily through its lead candidate OST-HER2. The company operates as a single segment and is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,396,831) | $(3,876,859) |
| Loss Per Share (Basic & Diluted) | $(0.27) | $(0.18) |
| Cash and Cash Equivalents (End of Period) | $917,552 | $2,971,007 |
| Net Cash Used in Operating Activities | $(4,563,538) | $(3,441,884) |
| Net Cash Provided by Financing Activities | $5,211,260 | $1,053,000 |
| Total Current Liabilities | $16,952,769 | $11,764,460 |
| Convertible Notes (Current) | $1,342,942 | $0 |
| Accumulated Deficit | $(77,583,050) | $(67,186,219) |
Material Changes vs. Prior Period
- Significant Increase in Net Loss: Net loss increased by approximately $6.5 million (168%) compared to Q1 2025, driven primarily by a surge in Research and Development (R&D) expenses.
- R&D Expense Surge: R&D expenses jumped from $1.3 million in Q1 2025 to $7.4 million in Q1 2026. This increase is attributed to vendor expenses related to compiling data for the Phase IIb clinical trial for regulatory submissions.
- Financing Activity: The company raised significant capital in Q1 2026 through a warrant exercise inducement offering (approx. $3.4 million) and a Bridge Financing (approx. $1.8 million net), compared to minimal financing in the prior year quarter.
- Liabilities: Current liabilities increased by over $5 million, largely due to accrued consulting fees for regulatory support (Biolacuna Ltd) and the issuance of new convertible notes.
- Warrant Liability: Unlike Q1 2025, which included a $1.1 million gain from the change in fair value of warrant liability, Q1 2026 had no such gain as the warrants were reclassified to equity in April 2025.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. As of March 31, 2026, cash balances were insufficient to fund operations, with expected vendor and regulatory costs totaling approximately $20.0 million for the remainder of 2026.
- Regulatory Milestones: The company anticipates submitting a Biologics License Application (BLA) to the FDA and Marketing Authorization Applications (MAA) to the EMA and MHRA in the second quarter of 2026. Confirmatory clinical studies are expected to initiate in Q3 2026.
- Subsequent Events: On April 2, 2026, the company completed a Registered Direct Offering raising approximately $4.7 million. This qualified as a "Qualified Offering," triggering the automatic conversion of the $2.2 million Bridge Convertible Notes into common stock and warrants.
- Legal Contingency: The company accrued $1.38 million for an arbitration ruling regarding underwriter compensation from its IPO, which is recorded in accrued expenses.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to inadequate segregation of duties and insufficient personnel with appropriate accounting knowledge.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.7 million raised in the April 2026 Registered Direct Offering against the stated $20 million in expected costs for the remainder of 2026.
- Debt Conversion: Confirm the accounting treatment and dilution impact of the Bridge Notes conversion into equity following the April 2026 offering.
- Regulatory Timeline: Monitor the Q2 2026 submission dates for the FDA BLA and EMA/MHRA MAA, as delays could impact funding needs and valuation.
- Internal Controls: Assess the remediation plan for the material weaknesses in internal controls over financial reporting disclosed in Item 4.
- Accrued Liabilities: Review the composition of the $16.9 million in current liabilities, specifically the $9.9 million in consulting fees payable to Biolacuna Ltd.